AccuCinch Ventricular Repair System
Phase 2- Indications
- Heart failure
Company intelligence / Profile preview
Early feasibility and interim pivotal data show that the AccuCinch Ventricular Restoration System can significantly improve quality of life, cardiac structure and function in patients with HFrEF. The system has received FDA Breakthrough Device Designation and is currently being evaluated in a large international randomized controlled trial (CORCINCH-HF) designed to support premarket approval. Initial results are promising for functional capacity and reverse remodeling.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ancora Heart.